Country: United Kingdom
Language: English
Source: VMD (Veterinary Medicines Directorate)
Carprofen
Ceva Animal Health Ltd
QM01AE91
Carprofen
Chewable tablet
POM-V - Prescription Only Medicine – Veterinarian
Dogs
Anti Inflammatory NSAID
Authorized
2010-02-04
Revised: September 2022 AN: 01545/2022 Page 1 of 6 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Carprodyl Quadri 120 mg chewable tablets for Dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION ACTIVE SUBSTANCE: One tablet contains: Carprofen.........................................................120 mg For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Chewable tablet. Clover-shaped scored beige tablet The tablet can be divided into four equal parts. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES In the dog: Reduction of inflammation and pain caused by musculo-skeletal disorders and degenerative joint disease. As a follow-up to parenteral analgesia in the management of post-operative pain. 4.3 CONTRAINDICATIONS Do not use in pregnant and lactating bitches. Do not use in dogs aged less than 4 months in the absence of specific data. Do not use in cats. Do not use in dogs, suffering from cardiac, hepatic or renal disease, when there is a possibility of gastrointestinal ulceration or bleeding or where there is evidence of blood dyscrasia. Do not use in case of hypersensitivity to the active substance, to other NSAID and to any of the excipients. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES See sections 4.3 and 4.5. Revised: September 2022 AN: 01545/2022 Page 2 of 6 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS Use in dogs less than 6 weeks of age, or in aged dogs, may involve additional risk. If such a use cannot be avoided, dogs may require a reduced dosage and careful clinical management. Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity. Concurrent administration of potential nephrotoxic drugs should be avoided. NSAID can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated. As Read the complete document